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Approaches for the systematic review and evaluation of chemical toxicity are currently being recon-
sidered, with a speciﬁc focus on the evaluation of individual studies and their integration into the overall
body of evidence. This renewed interest has arisen, in part, as a result of several prominent reviews of
these approaches by special committees of the National Research Council (NRC), among others. We
conducted a critical evaluation of several available frameworks for evaluating study quality. We assessed
the criteria separately for human, animal, and in vitro studies as well as for systematic reviews. We then
evaluated commonalities across disciplines. We also considered the potential implications of applying
criteria frameworks and how they bear on fundamental risk assessment questions. We found that the
available frameworks within each discipline differed in terms of their intended purpose and level of
guidance for decision making. All the frameworks across disciplines shared common themes, however,
including the adequate reporting of speciﬁc details of study conditions and design/protocol, selection and
randomization of study groups (where applicable), outcome assessment methods and applicability (e.g.,
validity and reliability), avoidance of selective reporting, and the consideration of potential confounders
or bias. We identiﬁed the most informative study quality considerations, which will enable researchers to
implement more objective and standardized methods for evaluating studies and, ultimately, improve risk
assessment methods.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Study quality and risk of bias
Approaches to the systematic review and evaluation of the
toxicity of chemicals are currently being reconsidered. This has
arisen, in part, as a result of several prominent reviews by, among
others, special committees of the National Research Council (NRC).
The United States Environmental Protection Agency (US EPA) has
undertaken a process to reform its methods for assessments under
its Integrated Risk Information System (IRIS) and seeks input and
advice from stakeholders. A key element of these process reformse
one that can be applied routinely and similarly across the studies
under consideration as well as across assessments e is the identi-
ﬁed need for objective and standardizedmethods for evaluating the
“quality” of individual studies. The aim is to provide a consistent
and objective system for bringing study strengths and shortcom-
ings to bear on their evaluation as evidence of potential toxic. Rhomberg).
Inc. This is an open access article ueffects.
Exactly what is meant by a study's “quality” has not been
deﬁned precisely, or, at least, it has not been deﬁned in exactly the
sameway in different discussions of the issue. But the general sense
is that a review should include an assessment of the study design's
soundness for its immediate intended purposes; the adequacy of
precautions taken to avoid potential impacts on the results from
unintended or uncontrolled causes (that is, inﬂuences aside from
the one being tested); the care taken to execute the protocol
correctly; and the adequacy and completeness of the analysis as
well as documentation of the conduct and the results. All of these
factors ultimately bear on whether the results of the evaluated
study should be regarded as reliable and unambiguous for the
interpretation of causal associations between the substance and the
outcome of interest.
The term “risk of bias” has been applied to some, but not all, of
the evaluation criteria for data quality. Because it is a new term, it
appears that different discussants are assigning it varying mean-
ings, and it is important to understand the intended implications in
those discussants' particular uses of the term. The use of the word
“bias” implies that the concern is for sources of possible systematicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1 Note that, at this time, there is no comprehensive guidance document for the
IRIS risk of bias criteria system.
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from statistical ﬂuctuation (for example, because of small numbers
of animals investigated or because of difﬁculty maintaining air
concentration precisely at its target level). The use of the term “risk”
implies that the issue is the potential for directional bias, as opposed
to the determination that the biasing factor has indeed affected the
results. That is, what is assessed is the sufﬁciency of steps to
eliminate or control the inﬂuence of the biasing factor, rather than
an assessment of the degree to which particular experimental re-
sults might have, in fact, been skewed.
The NRC (2014) review of the IRIS process makes the distinction
as follows:
The committee notes that assessing the quality of the study is
not equivalent to assessing the risk of bias in the study. An
assessment of study quality evaluates the extent to which the
researchers conducted their research to the highest possible
standards and how a study is reported. Risk of bias is related to
the internal validity of a study and reﬂects study-design char-
acteristics that can introduce a systematic error (or deviation
from the true effect) that might affect the magnitude and even
the direction of the apparent effect. [emphasis added]
In their guidance on systematic review (which includes details
on conducting study quality assessments), the National Toxicology
Program's (NTP) Ofﬁce of Health Assessment and Translation
(OHAT) echoed the distinction between imprecision and systematic
error but went somewhat farther, by suggesting that the systematic
error potential noted in risk of bias is not just related to, but is, in
fact, equivalent to the evaluation of a study's internal validity (NTP,
2015a). Note, however, that OHAT's preliminary guidance, issued in
2013, was less clear about the distinction between study quality
and “risk of bias,” seemingly using the terms interchangeably (NTP,
2013a). Only in the ﬁrst applications of their risk of bias approach
(e.g., the assessment of bisphenol A; NTP, 2013b) did OHAT begin to
speciﬁcally refer to “risk of bias” as a term that is synonymous with
internal validity.
The concepts of risk of bias and study quality are nonetheless
related. Procedures to ensure quality, such as the use of standard-
ized methods, quality control procedures, and transparent report-
ing, are put in place to minimize the possibility of introducing
sources of bias. Standard protocols (such as Organisation for Eco-
nomic Co-operation and Development [OECD] guidelines for spe-
ciﬁc test types) are developed primarily to mandate steps to avoid
known pitfalls and to avoid inadvertent introduction of unknown
extraneous factors into an untested aspect of study design. Even
unbiased random error is unbiased only in the long run, over
multiple iterations of an experiment or study. In any one experi-
ment, however, the random ﬂuctuations can, by chance, be skewed
away from the true mean values. If quality and bias measures are to
be applied to individual studies, as many of these criteria systems
intend, there is not a very clear distinction between study-speciﬁc
random skewing and more systematic skewing potential. If the
possibility of systematic skewing is at issue, the question still re-
mains whether the factor actually affected the results of an indi-
vidual study and, if so, howmuch and inwhat direction. Frequently,
the direction and magnitude of skewing may be unknown. More-
over, it would seem that if one examines two studies with identical
risk-of-bias proﬁles, except that one has a markedly larger number
of animals or number of distinct dose groups, then this measure of
quality (and not of bias) would affect the perceived dependability of
the measured results as an index of the true causative relationship
being investigated e that is, it would affect internal validity.
Another caveat about the use of the term “risk of bias” is that
there are some aspects of bias that operate at the level of collectionsof studies emost notably, publication bias. For a study for which all
the potential extraneous factors have been controlled, most of the
evaluation systems will concur about its internal validity. But the
choice of what studies to publish, what results of those studies to
feature and document in the publications, which among several
alternative analysis processes to pursue, whether those manu-
scripts are accepted for publication, and even what studies to un-
dertake in the ﬁrst place all can affect and bias the array of
outcomes available in the literature, even if each individual study
result that is reported is objective and reliable. Care must be taken
in projecting the evaluations of quality or bias for individual studies
into a characterization of the overall reliability of the body of
studies collectively.
1.2. Methods
We conducted an evaluation of several of the available study
quality criteria systems (Table 1), pulling out and systematically
comparing the speciﬁc criteria that the systems require evaluators
to examine for each rated study. The intent is that this analysis will
help further the general discussion about available study quality
evaluation systems and the features that should be adopted in any
system that might be established as part of the larger risk assess-
ment methods improvement effort. Because the types of studies
considered (i.e., animal, in vitro, human, and systematic reviews)
have different designs e and, thus, different considerations for
quality ewe have evaluated these types of evidence separately and
have summarized them in four separate tables (Tables 3e6).
We assessed the following systems for evaluating the quality of
studies or systematic reviews: the Klimisch system (Klimisch et al.,
1997); OECD Guidance Document (GD) 34 (OECD, 2005); the
Toxicological Data Reliability Assessment Tool (ToxRTool)
(European Commission, Undated); the approaches that have been
used in recent IRIS systematic review documents (US EPA, 2013),
notably the recent risk-of-bias evaluations for inorganic arsenic (US
EPA, 2014a)1; the framework being developed by NTP's OHAT (NTP,
2013a, 2015a,b), as applied to the risk-of-bias assessment of per-
ﬂuorinated compounds (NTP, 2013b,c); Animal Research: Reporting
of In Vivo Experiments (ARRIVE) guidelines for animal research
(Kilkenny et al., 2010); the Navigation Guide for systematic reviews
(Koustas et al., 2013, 2014; Woodruff and Sutton, 2014; Johnson
et al., 2014; Lam et al., 2014), the “assessment of multiple system-
atic reviews” (AMSTAR) system (Shea et al., 2007); the “strength-
ening the reporting of observational studies in epidemiology”
(STROBE) system (von Elm et al., 2007a,b,c,d,e); and the Systematic
Approach for Scoring Human Data, as developed by Money et al.
(2013). The types of studies (i.e., human, animal, in vitro, system-
atic reviews) addressed in each system are summarized in Table 1.
The speciﬁc criteria for each system are summarized in four tables,
one each for: human studies (Table 3), animal studies (Table 4),
in vitro studies (Table 5), and systematic reviews (Table 6). Several
of the criteria systems cover more than one of the study types.
Although these 10 particular criteria systems do not exhaust the list
of those that have been put forth, they provide a good overview of
the main systems aimed at broad usage. Overall, the criteria sys-
tems differ in their purpose and speciﬁc recommendations e some
only provide suggestions for information that should be reported
by study authors, others suggest speciﬁc criteria that should be
fulﬁlled by study authors, and others provide rating scales for use to
assess the relative level of quality for a study based on the scores it
receives. The entries used in the tables correspond to each of these
Table 1
Frameworks for evaluating study quality criteria.
Study quality criteria system (publication year) Human
studies
Animal
studies
In vitro
studies
Systematic
reviews
Integrated Risk Information System (IRIS) Risk of Bias (RoB) evaluation (2013, 2014)a X X X
The National Toxicology Programs (NTP's) Ofﬁce of Health Assessment and Translation (OHAT) approach
(2013, 2015)
X X X
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) system (2007) X
Money et al. approach (2013) X
Navigation Guide (2013, 2014) X X X
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (2010) X X
Klimisch System (1997) X X
Organisation for Economic Co-operation and Development (OECD) Guidance Document (GD) 34 (2005) X X
Toxicological Data Reliability Assessment Tool (ToxRTool) (2009) X X
Assessment of Multiple Systematic Reviews (AMSTAR) System (2007) X
Note: (a) Note that no ofﬁcial risk of bias assessment guidance has been published by the United States Environmental Protection Agency (US EPA); some aspects were
discussed in a 2013 document (US EPA, 2013), and more detailed information is contained in the 2014 Draft Development Materials for inorganic arsenic (US EPA, 2014a).
Table 2
General requirements for good laboratory practice (GLP) animal studies.
Speciﬁc criteria
Personnel, facilities, and procedures
Personnel with documented and relevant education, training, and experience
Quality Assurance Unit to maintain quality control (quality assurance plans provided by study director)
Test facilities of suitable size and construction, with separate areas for tasks, to avoid contamination
Written Standard Operating Procedure (SOP) and study protocol
Reagents, solutions, and test substance(s)
Reagents and solutions labeled; test chemicals and controls properly identiﬁed and stored to prevent contamination and deterioration
Documentation of identity, strength, purity, composition, stability, source, and batch of test chemical(s)
Animal care
Animal identiﬁcation system
Appropriate bedding materials and cleaning of animal housing
Feed and water analyzed for contaminants that may interfere with study
Documentation of animal characteristics (number, species, strain, age, sex, weight, source)
Dosing procedure and experimental protocol
Document:
Dose groups, substance preparation (including vehicle[s]), administration route
Speciﬁcations for acceptable levels of contaminants in test substance
Rationale for method used
Type and frequency of tests, analyses, and other measurements
Statistical methods used
Protocol changes or deviations
Data entry
Documentation of date of collection and signature/initials of person entering data
Final report
Document:
Dates of study initiation and completion
Objectives and procedures/methods (including all stated above) and any deviations from protocol
Names of all personnel involved in the study
Data calculations and statistical analyses
Findings of quality assurance inspections
Storage location of all specimens, raw data, and ﬁnal report
Archiving
Retain raw data, records, protocols, specimens, correspondence, and ﬁnal report
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2. Findings
Although all of the reviewed systems are currently being applied
for similar purposes for use in hazard and risk assessment, each
differs in terms of its initial objectives and evolution. As discussed
further below, ARRIVE and STROBE were developed as publication
criteria (i.e., their purpose is to deﬁne reporting requirements);
Klimisch and ToxRTool incorporate reporting criteria as well as
study design and conduct criteria; OECD GD 34 is a study validation
system; the IRIS document approaches, the OHAT framework, and
the Navigation Guide speciﬁcally address risk of bias (internal
validity); and the AMSTAR system includes reporting requirements
as well as a checklist for assessing speciﬁc aspects ofmethodological quality in systematic reviews.
Broadly speaking, these criteria systems ﬁt into one of three
historical strains: (1) guidelines for study design and conduct ac-
cording to standardized protocols (e.g., OECD Guidelines Studies),
(2) standards for thorough recordkeeping and reporting of study
conduct and results (e.g., Good Laboratory Practice [GLP] stan-
dards), and (3) methods for evaluating the quality of existing
studies along a number of criteria and assessing or rating the
overall reliability of a study (e.g., Klimisch ratings). Clearly, these
three strains are related, because they refer to an overarching set of
standards of good practice and the avoidance of widely recognized
pitfalls. Guidelines for design and conduct require that new studies
follow practices that aim to avoid issues that can compromise the
reliability and informativeness of results; reporting standards aim
to ensure that new studies document adherence to good practices
Table 3
Overview of guidance systems for the quality evaluation of human studies.
Guidance criteria IRIS RoB* OHAT* STROBE Money et al. (2013)a Navigation Guideb,*
Study objectives Report Report
Study design and setting (e.g., date, location) Report Report Report
Participant characteristics
(e.g., age, race, sex, eligibility criteria)
Report Report Reportc
Study size Report Report Report
Sufﬁcient so that estimates not subject to high imprecision Y/N
Consistent recruiting methods Score
Study power analysis Report
Blinding
Participants Score Score
Outcome assessors Score Score Score
Participation rate/attrition Report Report
Attrition similar across groups Score Score
Loss to follow-up minimized Score Score Y/N
Potential for selection bias Discuss
Inclusion/exclusion criteria Report
Comparison groups Report Report
Similar to cases/exposed Score Score
Statistical methods Score Score Report
Appropriate techniques Y/N*
Data sources Report
Data measurement methods Report Report Report
Sources of bias and confounding Discuss Discuss Report
How confounding and bias addressed Report,
Score
Report,
Score
Report Score
Co-exposures controlled for Score Score
Possibility for bias reduced through designd Y/N*
Exposure characterization
Exposure levels and unit of measurement Report Report Report
Measurement sensitive and applied consistently Score Score Score
Exposure assessment made independent of outcomee Y/N
Validated outcome assessment methods Score Score Report Y/N
Outcome assessed independent of exposure status Y/N
Potential for outcome misclassiﬁcation Discuss
Adherence to study protocol Score Score
Study results Report Report Report Report Report
Detailed results, adjusted and unadjusted analyses Report Report Report Report
Results of sensitivity or other analyses Report
All measured outcomes reported Score Score Score
Limitations Report Report
Interpretation Report
Unambiguous Interpretationf Y/N
Generalizability Discuss Report
Funding source/COI statement Report Report Report Score
“Other” bias Score
Notes: COI ¼ Conﬂict of Interest; IRIS RoB ¼ Integrated Risk Information System Risk of Bias; OHAT ¼ Ofﬁce of Health Assessment and Translation (part of the National
Toxicology Program); STROBE ¼ Strengthening the Reporting of Observational Studies in Epidemiology; US EPA ¼ United States Environmental Protection Agency.
Guideline Key: Discuss ¼ Address this issue in some way (no speciﬁc criteria and not considered directly as part of the scored 15 questions in the IRIS RoB framework);
Report ¼ Reporting requirement; Score ¼ Scored for category based on the extent that issues were addressed; Y/N ¼ Criteria fulﬁlled (i.e., “Yes” or “No”).
Sources: IRIS RoB ¼ US EPA (2013, 2014a).
OHAT ¼ NTP (2013a,c).
STROBE ¼ von Elm et al. (2007a,b,c,d,e).
Navigation Guide ¼ Koustas et al. (2013, 2014); Woodruff and Sutton (2014); Johnson et al. (2014); Lam et al. (2014).
* Indicates a criteria (or system) that is speciﬁcally stated as a risk-of-bias consideration. All the criteria in the IRIS, OHAT, and Navigation Guide approaches are considered risk
of bias issues. The only exception is the “Generalizability” criteria for IRIS, which is discussed in the context of study quality in US EPA's original guidance document (US EPA,
2013).
(a) The quality criteria below are speciﬁc to Money et al. (2013); the authors also state that all methodology and results should be “comprehensively and transparently”
reported according to guidelines such as the STROBE guidelines. If all the criteria detailed in this table are fulﬁlled, overall, the study is considered “reliable without restriction.”
Money et al. (2013) also provide guidelines for overall ranking of a study if some criteria are missed, which correspond with overall ratings of “reliable with restrictions,” “not
reliable,” or “not assignable.”
(b) The Navigation Guide was originally developed for systematic reviews of animal studies, but it has also been applied for epidemiology studies in a systematic review of
perﬂuorinated compounds (Johnson et al., 2014).
(c) The authors stipulate that this information should be provided separately for cases and controls in caseecontrol studies or exposed and unexposed groups in cohort/cross-
sectional studies.
(d) Through statistical methods or sensitivity analyses.
(e) Authors emphasize the importance of well-established, validated, quantitative exposure assessment methods at the individual level, with as little measurement error as
possible.
(f) Methods (and, thus, results) are without appreciable limitations, such that the reader is able to draw causal inference with respect to the exposure and outcome under
consideration.
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studies in assessments; and quality rating systems aim retrospec-
tively to score adherence to such principles and codify judgmentsabout how well they have been met and, hence, how reliable the
studies should be deemed to be.
Indeed, as we discuss further below, some retrospective quality
Table 4
Overview of guidance systems for the quality evaluation of animal studies.
Guidance criteria ARRIVE Klimischa OECD GD 34b ToxRToolc IRIS
RoB*
OHAT* Navigation
guide*
Study objectives Report Report Optional Report
Study design and setting
(e.g., dates of dosing and evaluation periods)
Report Report Reportd Reportd Reporte
Followed OECD procedure? GLP conditions? Optional Report
Animal characteristics
(species, age, stage, sex, weight)
Report Score Report Report Reportd Reportd Report
Substance (composition, CAS#, purity) Report Score Report Report Report Report Report
Total study size (number of control and experimental groups) Report Score Report Y/N Report Report Report
Number of animals per dose group Report Score Report Report Reportd Reporte Report
Source of animals Report Report Reporte
Additional relevant information (genetic modiﬁcation, genotype, health status) Report Report Report Report
Attrition minimized Score Score Report
Blinding and Subject Randomization Report* Report* Score Score Score
Experimental unit (single animal, cage of animals) Report Report Report
Husbandry details (breeding program, access to food and water, light and dark cycle) Report Score Report Y/N Score Scored Report
Housing conditions Report Score Report Y/N Score Score Report
Experimental procedure Report Report Score Reportd Report
Dose groups, substance preparation, administration route Report Score Report Report Score Reportd Report
Time and location of dose administration Report Report Report Score Reportd Report
Rationale for method used Report Report
Impact of protocol Deviations Score Score
Outcome assessment methods Report Score Report Y/N Score Score
Statistical methods used Report Report Y/N Score Score
Results, adjusted and unadjusted analyses Report Report Y/N Score Score Score
Report non-signiﬁcant results Report Score Score Score
Baseline data for each experimental group Report Report Score
Number of subjects included in statistical analysis and rationale for exclusion of subjects Report Report Score Score
Reliability and appropriateness of test for endpoint analyzed Report Y/N Score Score
Consideration of confounding or modifying variables Score Score
Precision of results (standard deviation, conﬁdence interval) Report Report Report
Description of adverse events observed Report Score Report Score
Dose/concentration relationship Score Report
Limitations Report Report
Interpretation and Implications Report Report
Generalizability Report Report Report
Funding source Report Report Report Score
“Other” study design bias Discuss
Notes: ARRIVE¼ Animal Research: Reporting of In Vivo Experiments; CAS #¼ Chemical Abstracts Service Number; GLP¼ Good Laboratory Practice; IRIS RoB¼ Integrated Risk
Information System Risk of Bias; OECD GD ¼ Organisation for Economic Co-operation and Development Guidance Document; OHAT ¼ Ofﬁce of Health Assessment and
Translation (part of the National Toxicology Program); ToxRTool ¼ Toxicological Data Reliability Assessment Tool.
Guideline Key: Discuss ¼ Address this issue in some way (no speciﬁc criteria and not considered directly as part of the scored 15 questions in the IRIS RoB framework);
Report ¼ Reporting requirement; Score ¼ Scored for category based on the extent that issues were addressed; Y/N ¼ Criteria fulﬁlled (i.e., “Yes” or “No”).
Sources: ARRIVE ¼ Kilkenny et al. (2010).
Klimisch ¼ Klimisch et al. (1997).
OECD GD 34 ¼ OECD (2005).
ToxRTool ¼ European Commission (Undated).
IRIS RoB ¼ US EPA (2013, 2014a).
OHAT ¼ NTP (2013a,c).
Navigation Guide ¼ Koustas et al. (2013, 2014); Woodruff and Sutton (2014); Johnson et al. (2014); Lam et al. (2014).
* Indicates a criteria (or system) that is speciﬁcally stated as a risk-of-bias consideration. All the scoring criteria in the IRIS, OHAT, and Navigation Guide approaches are
considered risk of bias issues.
(a) This table addresses only the issues that are explicitly stated in the Klimisch et al. (1997) document. Studies receiving Klimisch scores of “1” inherently incorporate all of the
requirements of US EPA, US FDA, or OECD GLP guidelines and, thus, would meet other quality criteria not covered in this table. Although all the individual elements in GLP and
test guidelines are not listed here, they are considered in Klimisch scoring and are important to consider when evaluating study reliability.
(b) OECD Guideline 34, “Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment.” The OECD guidelines
outline criteria for the development of new test methods, rather than assessment criteria for completed studies.
(c) Criteria marked “Report” for ToxRTool must be fulﬁlled in order to achieve a “reliable” score.
(d) Study characteristics that should be reported are not explicitly stated but are provided in example tables for animal studies in the arsenic and perﬂuorinated compounds
assessments, for IRIS and OHAT, respectively.
(e) The Navigation Guide system has speciﬁc reporting requirements for reproductive and developmental study methodologies.
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of adherence to the speciﬁc design and documentation standards.
Current interest in developing a standardized and widely appli-
cable system for examining and evaluating study quality refer back
to precedents in all three of the historical strains named above. Our
discussion of these systems below tries to respect the different
original purposes but nonetheless examine the various precedents
for insight into useful and necessary properties of a new study
quality evaluation system.2.1. Human study quality criteria systems
Some of the systems that are relevant to epidemiological and
other human studies (IRIS, OHAT, STROBE, the Navigation Guide,
and Money et al., 2013) are quite similar, while others vary
considerably in their recommendations for addressing study
quality. The STROBE guidelines (von Elm et al., 2007a,b,c,d,e) are
limited to reporting requirements, i.e., the criteria are lists of
methods and issues that all studies should report (e.g., study size
Table 5
Overview of guidance systems for the quality evaluation of in vitro studies.
Guidance criteria ARRIVE Klimischa OECD GD 34b ToxRToolc
Study objectives Report Report Optional
Study design and setting (date, location, etc.) Report Report
Test system and test method Score Report Y/N
Followed OECD procedure? GLP conditions? Score Report Optional
Substance (composition, CAS#, purity, source) Report Score Report Report
Source of test system and substance Score Report Y/N
Total study size (number of control and experimental groups) Report Report
Study size e number of replicates Report Y/N
Blinding and subject randomization Report* Report*
Experimental procedure Report Score Report Y/N
Dose group, substance preparation, administration route Report Score Report Report
Positive or negative controls Report Score Report Report
Outcome assessment methods Report Score Report Y/N
Statistical methods used Report Report Y/N
Results, adjusted and unadjusted analyses Report Report Y/N
Number of subjects included in statistical analysis (and rationale for exclusion of subjects) Report Report
Data on observations that may inﬂuence interpretation (pH shift, impurities, solubility) Score Report
Precision of results (standard deviation, conﬁdence interval) Report Report
Description of adverse events observed Report Report
Dose/concentrationeresponse relationship Report Score Report
Reliability and appropriateness of test for endpoint analyzed Score Report Y/N
Limitations Report Report
Interpretation and implications Report Report
Generalizability Report Report Report
Funding source Report
Notes: ARRIVE ¼ Animal Research: Reporting of In Vivo Experiments; CAS # ¼ Chemical Abstracts Service Number; GLP ¼ Good Laboratory Practice; OECD GD ¼ Organisation
for Economic Co-operation and Development Guidance Document; ToxRTool ¼ Toxicological Data Reliability Assessment Tool; US EPA ¼ United States Environmental
Protection Agency; US FDA ¼ United States Food and Drug Administration.
Guideline Key: Report ¼ Reporting requirement; Score ¼ Scored for category based on the extent that issues were addressed; Y/N ¼ Criteria fulﬁlled (i.e., “Yes” or “No”).
Sources: ARRIVE ¼ Kilkenny et al. (2010).
Klimisch ¼ Klimisch et al. (1997).
OECD GD 34 ¼ OECD (2005).
ToxRTool ¼ European Commission (Undated).
* Indicates a criteria (or system) that is speciﬁcally stated as a risk-of-bias consideration.
(a) This table addresses only the issues that are explicitly stated in the Klimisch et al. (1997) document. Studies receiving Klimisch scores of “1” inherently incorporate all of the
requirements of US EPA, US FDA, or OECD GLP guidelines and, thus, would meet other quality criteria not covered in this table. Although all the individual elements in GLP and
test guidelines are not listed here, they are considered in Klimisch scoring and are important to consider when evaluating study reliability.
(b) OECD Guideline 34, “Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment.” OECD guidelines
outline criteria for the development of new test methods, rather than assessment criteria for completed studies.
(c) Criteria marked “Report” for ToxRTool must be fulﬁlled in order to achieve a “reliable” score.
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any recommendations regarding which methods are preferred, for
quality reasons, or how any of the listed criteria may affect study
results. In contrast, the other three systems require the evaluation
of the appropriateness of the chosen design and methods.
The Money et al. (2013) study developed a tiered study quality
system based on the Klimisch system for animal and in vitro studies
(Klimisch et al., 1997; see Section 2.2). Under this system, if a study
fulﬁlls a certain set of criteria, it can be considered “reliable without
limitations.” The remaining three tiers outline how to evaluate
studies missing some of these criteria as either “reliable with re-
strictions,” “not reliable,” or “not assignable” (i.e., do not contain
sufﬁcient detail regardingmethodology to assess quality or are only
available as short abstracts or summaries in secondary literature).
Although bias is considered within the criteria, Money et al. (2013)
deﬁne study quality more broadly than issues of bias.
The OHAT risk-of-bias criteria, which include “15 questions” for
addressing risk of bias, go a step further than the system developed
by Money et al. (2013). The assessor is told to assign a rating of
“þþ,” “þ,” “,” or “ ” for each question based on the degree to
which the study addresses it, corresponding to “deﬁnitely low,”
“probably low,” “probably high,” or “deﬁnitely high” risk of bias.
The questions vary slightly among study types (cohort, cross-
sectional, and case series), depending on applicability. The ofﬁcial
NTP OHAT handbook and supplemental materials published in
2015 provide explicit instructions and examples regarding how toassign a risk-of-bias rating for each question (NTP, 2015a,b). For
example, for the question, “Did selection of study participants
result in appropriate comparison groups?,” NTP states that, for
cohort and cross-sectional studies, “deﬁnitely low risk of bias”
means that there is direct evidence that the exposed and unex-
posed subjects were similar (e.g., recruited from the same eligible
population via the same method of ascertainment, recruited within
the same time frame, and had similar participation/response rates)
(NTP, 2013a, 2015b).
Additional explanation of how to speciﬁcally apply the risk-of-
bias process methods can also be found in the NTP perﬂuorinated
compounds systematic review document (NTP, 2013c) and the draft
risk-of-bias assessment for bisphenol A and obesity (NTP, 2013b).
Note that OHAT guidance now speciﬁcally distinguishes between
risk of bias and methodological quality (NTP, 2015a), but, in pre-
liminary OHAT guidance, the two concepts appeared to be inter-
changeable (NTP, 2013a). The OHAT guidance on how to determine
overall tiers of quality for each study is clear. The system guides the
reader through the requirements for a study to be considered “Tier
1,” “Tier 2,” or “Tier 3,” based on overall risk of bias.
The IRIS risk-of-bias criteria were adapted from the OHAT sys-
tem, but appear to have been slightly modiﬁed. The IRIS criteria are
detailed and explicit, assigning a score for each criterion based on
the degree to which the study addresses it. At this time, the most
detailed instructions regarding the IRIS criteria are provided in the
Draft Development Materials for Arsenic (US EPA, 2014a), because
Table 6
Criteria for the quality evaluation of systematic reviews.
Guidance criteria IRIS OHAT AMSTAR Navigation
guide
Review objective identiﬁed Y/N Y/N Y/N
A priori design/protocol for the review Y/N Y/N Y/N Y/N*
Comprehensive literature search of more than one database Y/N Y/N Y/N Y/N
Details of search strategy
(Including: Date of search and any updates, databases used, a priori inclusion criteria)
Report Report Report Report
Inclusive literature approach useda Y/N
Iterative literature identiﬁcation
(i.e., contacting subject matter experts for sources for grey literature)
Y/N
Two independent reviewers of data Y/N Y/N Y/N Y/N
Procedure for disagreements between study reviewers Y/N Y/N Y/N Y/N
List of excluded and included studies Y/N* Y/N Y/N
Reasons for study exclusion Y/N* Y/N* Y/N
Study characteristics reported (e.g., in a table)b Y/N Y/N
Study results provided without restriction (based on statistically signiﬁcant or positive associations) Y/N*
Assessment and documentation of the scientiﬁc quality of each study Score* Scorec* Y/Nd* Score*
If studies assessed for individual quality, considerations/criteria transparently detailed Y/N Y/N Y/N Y/N
Individual study quality scores provided in tabular format Y/N Y/N Y/N
Classiﬁcation of individual studies into quality tiers Optional Optional Y/N
Appropriate methods to combine ﬁndings across studiese Y/N Y/N Y/N
Overall conﬁdence rating for body of evidence Score Score Score
Consideration of risk of bias, temporality, magnitude of effect, doseeresponse, unexplained inconsistency, relevance of
endpoints, and imprecision
Score* Score* Score*
Qualitative assessment of publication bias Y/N* Y/N* Score*
Determination of level of evidence for health effect Score Score
Overall conclusions for hazard identiﬁcation Scoref Scoreg Scoreh
Statement of possible conﬂict of interest in both systematic review and included studies Y/N Y/N Score*
Discussion of deviations from review protocol
(provided and justiﬁed)
Y/N
Notes: AMSTAR ¼ Assessment of Multiple Systematic Reviews System; GRADE ¼ Grading of Recommendations Assessment, Development and Evaluation; IRIS ¼ Integrated
Risk Information System; OHAT ¼ The Ofﬁce of Health Assessment and Translation.
Guideline Key: Report ¼ Reporting requirement; Score ¼ Scored for category based on the extent that issues were addressed; Y/N ¼ Criteria fulﬁlled (i.e., “Yes” or “No”).
Sources: IRIS ¼ US EPA (2013).
OHAT ¼ NTP (2013a,c).
AMSTAR ¼ Shea et al. (2007).
Navigation Guide ¼ Koustas et al. (2013, 2014); Woodruff and Sutton (2014); Johnson et al. (2014); Lam et al. (2014).
* Indicates a criteria (or system) that is speciﬁcally stated as a risk of bias consideration.
(a) Reviewers should err on the side of inclusion (i.e., it is better to include a study in the systematic evaluation and examine the impact of potential limitations, rather than
exclude a study and lose any information it could have provided).
(b) IRIS criteria require that very speciﬁc details be provided (e.g., description of comparison groups and prevalence of important confounders in these groups as well as the
preference that reviewers present study sizes by exposure/outcome group).
(c) OHAT's risk of bias system is the same as IRIS but with fewer details provided in the guidance. OHAT states these criteria are based on the Guyatt et al. (2011b) “GRADE”
guidelines for risk of bias.
(d) No speciﬁc requirements for quality criteria; AMSTAR simply states that the criteria should be developed a priori and described.
(e) For pooled results, a test should be done to ensure that studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity). If heterogeneity
exists, a random effects model should be used and/or the clinical appropriateness of combining these results should be considered.
(f) The quality of the individual studies are qualitatively evaluated and pooled to form overall conclusions on the body of evidence depending on the likelihood that bias and
confounding indicate possible alternative explanations for associations. Categories are “sufﬁcient,” “suggestive,” or “inadequate” epidemiologic evidence of an association
consistent with causation, or “epidemiologic evidence consistent with no association.”
(g) Based on the evidence, categorize as “known,” “presumed,” or “suspected” hazard to humans or “not classiﬁable or not identiﬁed to be a hazard to humans.”
(h) Based on the evidence, categorize a particular exposure as “known to be toxic,” “probably toxic,” “possibly toxic,” “not classiﬁable,” or “probably not toxic” (in this
framework, this is applied speciﬁcally to reproductive and developmental health).
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vided recommended ratings (“þþ,” “þ,” “,” or “”) are based on
the likelihood of bias (deﬁnitely low, probably low, probably high,
or deﬁnitely high risk of bias). The Draft Development Materials for
Arsenic (US EPA, 2014a) provide a table to use for determining the
overall quality tier for each study (i.e., “high” or “low” overall risk of
bias). The overall tier is determined based on how many of the
individual 15 questions were rated as a “” or “.” The table lacks
clarity, especially in comparison to OHAT's guidance on overall
quality tiers, and may be difﬁcult for some readers to use as
intended. Finally, it should be noted that, in addition to the 15
questions provided in the arsenic draft development materials, the
general guidelines US EPA put forth for IRIS assessments based on
the 2011 NRC recommendations (US EPA, 2013) provide additional
qualitative guidance for evaluating study quality and general con-
siderations that should be used to make quality judgments. In thisdocument, however, the authors never use the phrase “risk of bias”
when discussing study quality, and it appears that, based on further
recommendationsmade by NRC in 2014 (NRC, 2014), IRIS shifted its
focus from general study quality to speciﬁcally addressing risk of
bias (as seen in the arsenic assessment). Note that although NRC
recommended rigorously evaluating study quality, the NRC review
does not speciﬁcally suggest an assessment of “risk of bias” (NRC,
2011).
The Navigation Guide system (Koustas et al., 2013, 2014;
Woodruff and Sutton, 2014; Johnson et al., 2014; Lam et al.,
2014), although targeted speciﬁcally at systematic reviews of ani-
mal studies, has also been applied to human data. This system
shares many of the same criteria as the OHAT system, and the au-
thors state that their risk of bias assessment was also adapted from
the Agency for Healthcare Research and Quality (AHRQ, 2012) and a
series of papers by Guyatt et al. (2011a,b,c,d,e,f,g,h,i) and Balshem
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whether there is a “low risk of bias,” a “probably low risk of bias,” or
a “high risk of bias” (or “not applicable,” when appropriate) for a
series of risk-of-bias criteria. Unlike the OHAT system, however, in
the Navigation Guide system there are fewer criteria to score risk of
bias. The Navigation Guide includes a set of eight questions
addressing the issues of consistent recruitment of participants,
exposure group concealment (personnel and outcome assessors),
exposure measurement methods, methods to reduce confounding,
outcome reporting, and ﬁnancial conﬂict of interest. This last cri-
terion distinguishes the Navigation Guide from IRIS and OHAT.
Although IRIS and OHAT state that the funding source of a study
should be reported, the Navigation Guide scores each study for risk
of bias based on funding source.
Only two of the available systems that were reviewed (IRIS and
OHAT) provide any guidance on rating the quality of controlled
human exposure studies, which incorporate some concepts that are
relevant to animal studies (e.g., storage of samples, randomization,
blinding) and also some that are speciﬁc to human subjects (e.g.,
participant inclusion/exclusion criteria). These studies, as well as
other studies that may be outside of traditional deﬁnitions (e.g.,
biomonitoring studies), may require a rating approach that com-
bines considerations from different study types. Good Clinical
Practice (GCP) guidelines may also be useful for evaluating the
quality of these types of studies (ICH, 1996).
Despite differences in their intended application, there are some
similarities among the ﬁve human study criteria systems reviewed.
At least four of the ﬁve systems clearly note that reporting, if not
scoring, is needed for the following issues: blinding (for outcome
assessors and for personnel and participants in controlled human
exposure studies), participation rate/attrition, the validity of the
comparison groups, statistical methods, data measurement
methods, sources of bias/confounding and how they were reduced,
exposure characterization, appropriate outcome assessment
methods, and the presentation of both adjusted and unadjusted
results of analyses. All ﬁve systems also require that authors report
funding source/conﬂict of interest; however, only the Navigation
Guide scores studies based on funding source. Only two out of the
ﬁve systems mention the importance of evaluating the generaliz-
ability of results, reporting the study limitations, and considering
the interpretation of the results. Regarding interpretation, in
particular, only the Money et al. (2013) guidelines state that a
reliable study should allow for “unambiguous interpretation;” in
other words, the methods and results are sufﬁcient so that the
reader can draw causal inferences with respect to exposure and
outcome without appreciable limitations or uncertainty. Finally,
only the IRIS system mentions evaluating study power via statis-
tical analysis, and only the STROBE guidance (von Elm et al.,
2007a,b,c,d,e) and Navigation Guide note that authors should al-
ways report the objectives of the study.
2.2. Animal and in vitro study quality criteria review systems
Like the human study criteria systems, the systems aimed at
assessing animal experiments e ARRIVE, Klimisch, OECD GD 34,
ToxRTool, IRIS, and OHAT e vary in their recommendations and the
purpose of their criteria. Several of these systems, however, are
interrelated and based around the same underlying principals. For
example, the Klimisch system is based heavily on the principals of
GLP and OECD test guidelines. The ToxRTool is a reﬁnement of the
general criteria described by Klimisch.
GLP principles merit a brief discussion. GLP is a quality man-
agement system for non-clinical studies that provides a framework
for how laboratory studies are planned, performed, monitored,
recorded, reported, and archived. There are several regulatoryagencies with GLP regulations or guidelines (US EPA, United States
Food and Drug Administration [US FDA], and OECD), each of which
vary slightly. In general, however, to be considered a GLP study, a
researcher must follow a detailed set of criteria that include speciﬁc
requirements for personnel, facilities, equipment, procedures, an-
imal care, test materials, study protocol, data recording, and
reporting (see Table 2). Perhaps most importantly, GLP requires
retention of all raw data and the preparation of a complete, inde-
pendently audited study report, including objectives, design,
methods, and all results and supporting data. Studies conducted
under GLP are generally considered robust and of sufﬁcient quality
for inclusion in causal analyses, because many of the precepts of
GLP requirements (and of deﬁned protocols such as OECD test
guidelines) are aimed at ensuring that quality considerations are
addressed in the study design and conduct. This said, it is none-
theless the case that the quality evaluation of GLP studies is a
function of their merits under the same set of evaluation criteria
that apply to the evaluation of other, non-GLP studies. Conducting
studies with established test guidelines and in compliance with
GLP regulations are requirements for acceptance by many regula-
tory authorities.
As noted above, GLP standards have heavily inﬂuenced several
of the quality criteria systems. The Klimisch system, while incor-
porating GLP and OECD guidelines, does not provide detailed
guidance on speciﬁc quality factors when used alone. ToxRTool
(European Commission, Undated) is a newer system that was
developed using Klimisch principles, but with the intention to add
more explicit criteria for assigning an overall Klimisch score
(Schneider et al., 2009). Klimisch et al. (1997) and ToxRTool
(European Commission, Undated) each outline scoring frameworks
for reporting requirements in completed studies in order to assign a
reliability classiﬁcation (“reliable without restriction,” “reliable
with restrictions,” “not reliable,” or “not assignable”). Both systems
outline reporting requirements (see Table 4) necessary to achieve a
“reliable” classiﬁcation as well as several additional considerations
weighted to assign reliability restrictions; however, the criteria
differ between the two systems. As noted previously, by design, the
ToxRTool guidelines are more explicit than the Klimisch et al.
(1997) guidelines on variables that should be considered to ach-
ieve a “reliable” classiﬁcation in each category. For example, the
ToxRTool provides more explicit guidance on how to differentiate
between Category 2, “reliable with restrictions,” and Category 3,
“not reliable,” which, using Klimisch alone, may be difﬁcult to
distinguish between (Schneider et al., 2009).
The ARRIVE guidelines (Kilkenny et al., 2010), based off of the
Consolidated Standards of Reporting Trials (CONSORT) checklist for
randomized clinical trials, provide an outline of “good reporting
requirements” for authors to consider during the writing stage of
their studies. Rather than providing a scoring framework with
which a paper can be rated, as in Klimisch et al. (1997) and ToxRTool
(European Commission, Undated), ARRIVE (Kilkenny et al., 2010)
provides guidelines intended to improve reporting quality but does
not address overall study quality.
As is the case with the epidemiological studies, IRIS also pro-
vides “15 questions” to address the risk of bias in animal studies (US
EPA, 2014a). The rating system (“þþ,” “þ,” “,” or “ ”) mirrors
that used for the epidemiological studies to determine the likeli-
hood of bias for each criterion (“deﬁnitely low,” “probably low,”
“probably high,” or “deﬁnitely high” risk of bias); however, the
questions vary slightly to account for the differences inherent to the
study type. The IRIS approach bases the overall quality tier (low or
high risk of bias) for each study on how many of the 15 questions
were rated as a “” or a “”, as described in Tables 1e10 and 1e11
of the Agency's Draft Development Materials for Arsenic (US EPA,
2014a).
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is not a quality criteria system for authoring or assessing completed
studies, but rather provides guidance for the development and
validation of new and updated study methods for hazard assess-
ment. In addition to guidelines for methodological considerations,
such as species, route of administration, and substance preparation,
OECD provides requirements for international validation, including
reproducibility and precision of results across laboratories, rele-
vance of the test to the outcome of concern, and uniform reporting
practices (OECD, 2005).
As with the human studies, the IRIS and OHAT rating systems
are very similar, and both include a set of 15 questions. The OHAT
guidelines, however, again provide more guidance on what con-
stitutes meeting the requirements for each respective score (NTP,
2015b). Further, the risk of bias guidance document (NTP, 2015b)
provides examples of acceptable methods and caveats for some
requirements. For example, for randomization, the guidance notes
that allocation without a clearly random component may be
acceptable for a “probably low risk of bias” rating, if the methods
would not “appreciably bias results” (NTP, 2015b). This determi-
nation, the guidance states, may require consultation with a stat-
istician. An example table for use in documenting the
characteristics/results and the study quality of animal studies is
provided in Table 4 of “Step 4: Assess Quality of Individual Studies”
of the perﬂuorinated compounds assessment (NTP, 2013c) and
Appendix 4 of the 2015 OHAT handbook (NTP, 2015a).
As with the IRIS and OHAT evaluation systems, the Navigation
Guide system (Koustas et al., 2013, 2014; Woodruff and Sutton,
2014) provides a system to determine whether there is “low risk
of bias,” “probably low risk of bias,” or “high risk of bias,” (or “not
applicable,” when appropriate) for a series of risk-of-bias criteria.
The Navigation Guide includes many of the same reporting re-
quirements of the other animal study systems. Unlike IRIS and
OHAT, however, there are fewer criteria to score risk of bias. The
Navigation Guide for animal studies includes a set of seven ques-
tions addressing the issues of sequence generation, allocation
concealment, blinding of outcome assessment (personnel and
outcome assessors), incomplete outcome data, selective outcome
reporting, and ﬁnancial conﬂict of interest. As noted in the previous
section on human studies, this last criterion distinguishes the
Navigation Guide. It is the only system that has a scoring system
that penalizes publications that are not funded by academic grants,
the government, or non-proﬁt organizations.
All of the study guidelines for animal studies consistently note
the importance of reporting the test method, animal characteris-
tics, (e.g., species, age, and sex), and the characteristics of the test
substance (e.g., purity, composition, and preparation). The use of an
established OECD guideline or GLPs are optional but are noted in
most of the guidelines. Further, reporting the methodology for the
determination of dose groups, route of administration, and housing
and husbandry conditions were key to obtaining a “reliable” score
in all of the scoring guidelines. The ARRIVE (Kilkenny et al., 2010),
OECD GD 34 (OECD, 2005), IRIS (US EPA, 2013, 2014a), Navigation
Guide (Koustas et al., 2013, 2014; Woodruff and Sutton, 2014) and
OHAT (NTP, 2013a-c) systems all stress the importance of reporting
blinding and subject randomization methods employed by the
study, noting that randomization methodology should minimize
differences in subject characteristics (such as age and body weight)2 Note that Good Laboratory Practice (GLP) guidelines require reporting all re-
sults, and, as such, the Klimisch systemwould also require this for an assignment of
Category 1. However, as discussed previously, the Klimisch system publication does
not explicitly discuss all of the requirements of GLP, and, as such, when used alone
(without referencing GLP), it does not explicitly require reporting all results.among groups. All of the guidelines require reporting the outcome
assessment methodology and results. However, only the OECD,
IRIS, Navigation Guide, and OHAT systems state that all results,
statistically signiﬁcant or not, should be reported.2 Only two sys-
tems (ARRIVE and OECD) require the reporting of study limitations
and study interpretation and implications.
In vitro studies are addressed in the ARRIVE (Kilkenny et al.,
2010), Klimisch et al. (1997), OECD GD 34 (OECD, 2005), and
ToxRTool guidelines (European Commission, Undated), with
criteria similar to those for the animal studies. However, only the
OECD, IRIS, Navigation Guide, and OHAT systems state that all re-
sults, statistically signiﬁcant or not, should be reported. Only two
systems (ARRIVE and OECD) require the reporting of study limita-
tions and study interpretation and implications.
2.3. Guidance systems for systematic reviews and evidence
integration
In addition to the individual study criteria systems, there are
several systems targeted at systematic reviews and evidence inte-
gration. In other words, these systems provide guidance on how to
review the results of numerous studies at one time and make
conclusions based on the strength of the overall body of evidence.
We reviewed the US EPA IRIS (US EPA, 2013, 2014a), NTP OHAT
(NTP, 2013a-c), Navigation Guide (Koustas et al., 2013, 2014;
Woodruff and Sutton, 2014), and AMSTAR (Shea et al., 2007)
criteria systems. Although the IRIS and OHAT systems containmany
of the same considerations e the requirement that an ex ante
design/protocol for the review should be established; details on the
search strategy must be provided; and the body of evidence must
be assessed with regards to temporality, magnitude of effect,
relevance of endpoints, and other Bradford Hill criteria e there
remain potentially important differences between the two systems.
For example, OHAT explicitly states that the objective of the sys-
tematic review must be stated, whereas this requirement is not
stated in IRIS. OHAT also explicitly states that the potential for
publication bias must be explored, but this issue is not brought up
in the IRIS guidelines. Both IRIS and OHAT lay out fairly speciﬁc
requirements for data reporting in systematic reviews; they state
that study characteristics, results, and study quality should each be
provided in tabular format.
The third systematic review system, the Navigation Guide sys-
tem (Koustas et al., 2013, 2014; Woodruff and Sutton, 2014) is
almost identical to the OHAT system. The only difference is that
OHAT speciﬁcally states that the literature identiﬁcation process
should be iterative, a stipulation that is not present in the Naviga-
tion Guide. The Navigation Guide provides guidelines on assessing
whether the methods to combine ﬁndings across studies (i.e., in a
meta-analysis) are appropriate, including tests for the heteroge-
neity of data. The OHAT guidance provides a short section about
considering and conducting a meta-analysis, stating that their
approach is very similar to the Navigation Guide system (NTP,
2015a).
The ﬁnal systematic review criteria system, AMSTAR (Shea et al.,
2007), addresses very similar issues to IRIS and OHAT but tends to
be less explicit in certain areas e speciﬁcally, assessment of indi-
vidual study quality and overall conﬁdence in the body of evidence.
Unlike IRIS and OHAT, the AMSTAR criteria are not continuous
measures and consist of 11 questions, all of which can be answered
“yes,” “no,” “can't answer,” or “not applicable.” Only two questions
address study quality: the ﬁrst requires only that methods of
quality assessment are recorded, and the second requires an
assessment of whether the criteria were “appropriate.” The only
description provided to denote what constitutes an “appropriate”
quality criteria is, “The results of the methodological rigor and
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conclusions of the review, and explicitly stated in formulating
recommendations” (Shea et al., 2007). Finally, AMSTAR provides no
questions regarding the overall conﬁdence in the available body of
evidence.
3. Conclusions
3.1. Similarities among criteria systems
Overall, the available study quality reporting and rating systems
differ slightly to substantially from one another in terms of their
intended purpose and the level of detail with which the reader is
guided when making decisions for each of the quality criteria. All
systems, however, including human, animal, and in vitro (when
applicable) share common themes. These important themes
include: adequate reporting of speciﬁc details of study conditions
and design/protocol; selection and randomization (when appro-
priate) of study groups; outcome assessment methods and appli-
cability; avoidance of selective reporting; and consideration of
potential confounders or bias.
3.2. Implications of the data quality criteria systems
There are broad similarities among the data quality criteria
systems, in that they all seek to note and document whether any
aspect of a study's design or execution might lead to outcomes that
may be affected by factors other than the one nominally being
examined for its ability to cause the outcomes of concern. That is,
the question for individual studies is primarily one of internal
validity e the lack of ambiguity about what the study itself can be
said to have demonstrated, accomplished through controlling all
potential inﬂuences aside from the one the study intends to test.
Good experimental design aims to eliminate the possible role of
such extraneous factors, and the criteria for most data quality
evaluation systems require documentation of the steps that a study
has taken to eliminate the ones that can be anticipated and
addressed.
The ultimate test of the success of experimental design is
repeatability; if all extraneous factors have been controlled, then a
true effect should appear consistently (within the limits of statis-
tical variability to be expected from the sample sizes used). Only the
OECD guidelines, however, explicitly refer to repeatability (OECD,
2005), and OECD standard protocols are notable for their
emphasis on documenting repeatability across practitioners. The
advantage of such rigid and tested protocols is their documentation
of reliability, but their potential disadvantage e at least for some
questions e is that they may not be aimed at new or intermediate
endpoints, particulars of underlying biology, or possible roles of
novel causation pathways or patterns of dose-dependence.
In particular, emerging technologies, such as high-throughput
screening, exemplify the challenges of evaluating study quality
with strict criteria systems. For example, although the NTP/US EPA/
National Institutes of Health (NIH) joint Tox21 database (NTP,
2013d) and US EPA's Toxcast program (US EPA, 2014b), which
each aim to screen numerous chemical compounds for potential
toxicity through the use of in vitro assays, perform some quality
control to ensure proper handling and veriﬁcation of the identity,
concentration, purity, and stability of chemical samples being
tested, there are no explicit quality criteria built into the processes
that evaluate other quality aspects of these assays. Owing to the
novelty of these methods, standardizing a set of quality criteria
speciﬁc to high-throughput assays may pose some challenges, but
it is an essential component of applying these data to risk assess-
ment decision making. Emerging techniques and other laboratory-speciﬁc research that have not been fully validated and veriﬁed by
accepted criteria have similarities to Laboratory Developed Tests
(LDTs) as deﬁned by US FDA for use in clinical diagnostics. US FDA is
currently working to develop quality management systems for
LDTs, which may be useful to adapt for other novel technologies.
Therefore, there will always be studies that do not fully follow a
pre-existing, well-standardized, and tested protocol, because they
seek to investigate possible causes, endpoints, or susceptibilities in
further species and strains beyond those existing in established
protocols. The evaluation criteria thus aim to document whether
anticipatable extraneous inﬂuences have been controlled for, and
the list of criteria focuses on measures to control those aspects of
design and conduct that, in our understanding and experience, can
affect outcomes. For one-off experiments, there is no empirical
validation that the controls imposed do, in fact, lead to repeatable
ﬁndings, and so the sufﬁciency of quality measures hinges on
whether the evaluation criteria indeed capture all of the aspects of
the study design and conduct that could have inﬂuence. The more
novel and unexplored the phenomenon being tested, however, the
more it is possible that the standard evaluation criteria do not ac-
count for some possible inﬂuence. In some cases, some forethought
may identify case-speciﬁc factors, beyond those in the standard
quality evaluation criteria, that should be addressed, and quality
evaluation systems should try to evaluate whether this has been
adequately done.
The extraneous inﬂuences that one aims to control through the
design and conduct of a study can broadly be categorized as either
sources of random error (increasing variance and, hence, statistical
ﬂuctuation in outcomes from one instance to another) and sources
of potential systematic error or bias. The evaluation systems we
reviewed do not make this distinction strongly, but the intent of
some criteria to examine a source of random or systematic error is
often clear, though implicit. For example, using vehicle controls
aims at reducing systematic error, and randomizing animals among
dose groups aims at reducing random error.
For studies of high quality, inwhich the criteria for good conduct
and design are mostly met, the various systems tend to agree in
their evaluations. The criteria systems diverge more when it comes
to dealing with studies that have a less-than-ideal design or
conduct. Some study quality systems simply document the lack of
complete fulﬁllment of one or more of their criteria. Others try to
rate the degree of shortcoming on individual criteria with scoring
systems. Although we have not explored it here, such scoring
schemes raise the question of how the less-than-ideal aspects of a
study should be aggregated across speciﬁc criteria to provide a
characterization of the “overall” quality of any one study. This is
distinct from the method that some systems have to arrive at
summary quality scores for the body of evidence, although both
applications share the question of how the assessments of indi-
vidual dimensions should add up to a useful and meaningful
summary measure. It is not immediately clear if or how a strength
in one dimension should be taken to compensate for a shortcoming
in another distinct aspect, how an overall score is to be interpreted
in terms of relative reliability of study results, or how alternative
scoring schemes should be compared to determine reliability and
effectiveness. These are issues that deserve further discussion.
Some criteria can be fully met and, therefore, cannot be
improved upon, but others (such as sample size or number of dose
groups) can always be expanded to a yet-better level, yieldingmore
statistical power, lower variance, or more detailed information
about patterns of dose dependency. The criteria for such factors
usually address whether these continuously improvable factors are
set at an “adequate” level, but the question of adequacy is, in part,
convention and, in part, a function of the ultimate application of the
data.
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bringing the evaluation of study quality to bear on larger risk
assessment questions. No study is absolutely ideal, if only because it
could have been conducted with larger sample sizes, more dose
levels, or with a broader range of conditions being investigated.
Some studies have shortcomings that, to a greater or lesser extent,
compromise the dependability of their nominal attribution of
outcomes to the tested variable. This is not to say that a study with
“greater” quality is necessarily correct or that one with “lesser”
quality is wrong. To conclude that a study's shortcomings actually
(rather than potentially) compromised its outcome is itself a sci-
entiﬁc conclusion that is hard to determine based on a single
instance. If studies disagree in outcome, one must decide whether
extraneous factors did indeed affect certain outcomes and which
outcomes are the ones actually (not just potentially) more affected
or less affected. For non-standard experiments, it must also be
entertained that the disagreements stem not from the aspects
measured in the quality criteria of the rating systems, but rather
from some poorly understood contingency of outcomes on a factor
that is not captured in the rating systems or, perhaps, is not even
recognized by current science.
It must also be remembered that study-speciﬁc ratings are
about internal validity, and rating criteria recognize and reward
study design that narrows the potential inﬂuential factors down
such that only the tested variable can plausibly inﬂuence the
outcome. That is, study outcomes are particular instances that are
intentionally constrained to a particular setting. Using the data
from such a study to make inferences about other matters (such as
human hazard potential, for instance) consists of generalizing from
these particular instances to other settings, and the applicability to
and informativeness of data from a study e no matter how high in
quality e to such other settings is a separate evaluation.
To summarize, although study quality evaluation systems vary
in the speciﬁcs of good study design, conduct, and reporting that
are examined, there are several elements that are nearly universally
named as essential to recognizing study results as robust and
reliable. For human studies, especially for observational epidemi-
ologic studies, these include aspects of care in identifying and
choosing study populations, investigating and adequately
addressing potential confounding factors, and avoiding selectively
reporting results. For animal studies, widely named factors include
careful and documented control of animal provenance, environ-
mental conditions, food, and water e all with a particular focus on
aspects that might introduce variations in outcomes that are not
attributable to the test agent. Also emphasized are the use of
appropriate control groups, the randomization of animals among
treatments, dependability and documentation of procedures for
exposure and for the evaluation of endpoints, and thorough
reporting of the outcomes examined. Blinding endpoint evaluators
to the dosing status of individual animals is often valued as well. It
is recommended that these widely recognized aspects of the
evaluation of study quality be incorporated into any further
development of evaluation systems.
In the particular case of standardized protocols, there are
recognized advantages that the repeatability and reliability of the
protocol have been empirically established. Repeatability of
execution among laboratories, and of the consistency across cases
of responses among control animals, have been documented.
Because the things that are standardized in standard protocols are
largely the same experimental design and conduct elements that
are recognized as key to quality evaluation, documented adherence
to protocols is itself a valuable index of study reliability that is
readily recognized in a consistent and repeatable way by different
practitioners. This said, there is an important role in toxicity eval-
uation for the broader set of studies that do not adhere to pre-existing protocols for various reasons, including the investigation
of novel endpoints, other species, or aspects of underlyingmodes of
action and the roles of early and intermediate responses in un-
derstanding apical toxicity. Study quality evaluation systems can be
valuable for guiding examinations of how (and how well) such
studies address concerns about potential impacts on rigor and
reliability that are addressed in more codiﬁed form in protocol
studies.
Note that systems vary in the way they distinguish (or fail to
distinguish) shortcomings on actual conduct from mere failure to
sufﬁciently document that the appropriate measures were actually
taken. One hopes that, knowing that studies will be judged more
useful and of higher quality when fully documented, the level of
expected documentation of study design and conduct in scientiﬁc
publications will increase.
Finally, it should again be emphasized that study quality eval-
uation bears on the reliability and robustness of the individual
study resultsewhether the outcomes can unambiguously be taken
as evidence of the effect of the agent in question in the particular
test system. While recognizing that test systems are chosen to be
informative about the further question of toxicity potential in hu-
man target populations, it should be recognized that study quality
is but one aspect e albeit a critically important one e in bringing to
bear and integrating the evidence that the studies provide during
the process of coming to ultimate judgments about the risk po-
tential of the agent in question in the population for which risks are
being assessed.
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